Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NMT1 | P30419 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974275 | 1.00 | MAPT (0.56) | MAPTALDH1A1KDM4ESMN1; SMN2GAA | |
| SCHEMBL30271575 | 0.81 | MAPT (0.59) | MAPTALDH1A1KDM4EPKMLMNA | |
| SCHEMBL19981414 | 0.81 | MAPT (0.59) | MAPTALDH1A1KDM4EPKMLMNA | |
| SCHEMBL1043517 | 0.81 | KDM4C (0.46) | MAPTALDH1A1PKMLMNAMEN1 | |
| SCHEMBL5176479 | 0.77 | MMP1 (0.71) | MAPTALDH1A1KDM4ESMN1; SMN2PKM | |
| SCHEMBL30764071 | 0.77 | MMP1 (0.71) | MAPTALDH1A1KDM4ESMN1; SMN2PKM | |
| SCHEMBL9360564 | 0.77 | MMP1 (0.71) | MAPTALDH1A1KDM4ESMN1; SMN2PKM | |
| SCHEMBL5177399 | 0.77 | MMP1 (0.71) | MAPTALDH1A1KDM4ESMN1; SMN2PKM | |
| SCHEMBL4139383 | 0.76 | ALDH1A1 (0.55) | ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL17655428 | 0.75 | SIRT3 (0.50) | MAPTALDH1A1KDM4ESMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| EP-3512602-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF Pharmaceuticals (CH) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050656-A2 | INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | MAPT 2930/4885ALDH1A1 2641/4885KDM4E 2977/4885 |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | MAPT 2930/4885ALDH1A1 2641/4885KDM4E 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.